Page 9 - Leonard Mazur News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Citius Pharmaceuticals, Inc Reports Fiscal Second Quarter 2023 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc Reports Fiscal Second Quarter 2023 Financial Results and Provides Business Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New jerseyUnited statesIlanit allenGreg salsburgLeonard mazurExchange commissionCompany nasdaqCitius pharmaceuticals incPrnewswire citius pharmaceuticals incSecurities exchangeDevelopment rd expensesJersey technology business tax certificate transfer programLido phaseHalo lido phaseMino lok phaseCitius pharmaceuticals

Citius Pharmaceuticals, Inc Reports Fiscal Second Quarter 2023 Financial Results and Provides Business Update

$29.1 million in cash and cash equivalents as of March 31, 2023; $15 million registered direct offering in May 2023 extends runway through May 2024 Halo-Lido Phase 2b trial completed with topline. | June 14, 2023

New jerseyUnited statesIlanit allenLeonard mazurGreg salsburgCompany nasdaqExchange commissionDevelopment rd expensesCitius pharmaceuticals incJersey technology business tax certificate transfer programSecurities exchangePrnewswire citius pharmaceuticals incLido phaseHalo lido phaseMino lok phaseCitius pharmaceuticals

Citius Pharmaceuticals, Inc Reports Fiscal Second Quarter 2023 Financial Results and Provides Business Update

/PRNewswire/ Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development.

New jerseyUnited statesGreg salsburgIlanit allenLeonard mazurJersey technology business tax certificate transfer programSecurities exchangeDevelopment rd expensesPrnewswire citius pharmaceuticals incCitius pharmaceuticals incCompany nasdaqExchange commissionLido phaseHalo lido phaseMino lok phaseCitius pharmaceuticals

Citius Pharmaceuticals (CTXR) Advances Mino-Lok Phase 3 Trial Achieving 85 of 92 Events to Date

Citius Pharmaceuticals (CTXR) Advances Mino-Lok Phase 3 Trial Achieving 85 of 92 Events to Date
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesLeonard mazurInfectious diseases society of americaCitius pharmaceuticals incCompany nasdaqInfectious diseases society

Citius Pharmaceuticals Advances Mino-Lok® Phase 3 Trial Achieving 85 of 92 Events to Date

CRANFORD, N.J., April 24, 2023 /PRNewswire/ Citius Pharmaceuticals, Inc. , a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical. | April 24, 2023

United statesLeonard mazurGreg salsburgIlanit allenPrnewswire citius pharmaceuticals incInfectious diseases society of americaCitius pharmaceuticals incSecurities exchangeUniversity of texas md anderson cancer centerExchange commissionCompany nasdaqInfectious diseases societyCitius pharmaceuticalsFast trackSecurities actSecurities exchange act